Advertisement
U.S. markets closed

Zai Lab Limited (ZLAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.10+0.12 (+0.57%)
At close: 04:00PM EST
20.68 -0.42 (-1.99%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close20.98
Open20.83
Bid20.25 x 1300
Ask22.39 x 800
Day's Range20.32 - 21.23
52 Week Range17.68 - 41.05
Volume542,748
Avg. Volume673,501
Market Cap2.093B
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-3.50
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.54
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ZLAB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zai Lab Limited
    Analyst Report: argenx SEArgenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more